NFL Biosciences SA
ALNFL
Company Profile
Business description
NFL Biosciences SA specializes in the research and development of medicines to combat tobacco addiction that use botanical and pharmaceutical agents. NFL-101 is company's core product, targeting smoking addiction. It is a clinically developed, botanical drug that contains an insignificant amount of nicotine and is composed of well characterized, natural tobacco leaf proteins.
Contact
199 rue Helene Boucher
Castelnau-le-Lez34170
FRAT: +33 411937667
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
4
Stocks News & Analysis
stocks
AI stocks post big gains in Q3. These are the winners and losers
Alphabet and Teradyne post big gains, while Salesforce and Adobe were down in the quarter.
stocks
12 picks for an income portfolio - Q3 2025 update
Fifteen months in and passive income growth has exceeded my target.
stocks
ASX’s only dividend aristocrat reports
Cyclical headwinds persist but loan book and industrial property prop up earnings.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,280.00 | 38.90 | -0.42% |
| CAC 40 | 7,971.78 | 109.76 | -1.36% |
| DAX 40 | 24,378.29 | 0.51 | -0.00% |
| Dow JONES (US) | 46,694.97 | 63.31 | -0.14% |
| FTSE 100 | 9,479.14 | 12.11 | -0.13% |
| HKSE | 26,957.77 | 183.15 | -0.67% |
| NASDAQ | 22,941.67 | 161.16 | 0.71% |
| Nikkei 225 | 47,944.76 | 2,175.26 | 4.75% |
| NZX 50 Index | 13,478.57 | 10.67 | -0.08% |
| S&P 500 | 6,740.28 | 24.49 | 0.36% |
| S&P/ASX 200 | 8,981.40 | 34.80 | -0.39% |
| SSE Composite Index | 3,882.78 | 20.25 | 0.52% |